SCHEMBL3533125

SCHEMBL3533125

CCOC(=O)c1cn(Cc2ccccc2)c2nc(S(C)(=O)=O)ncc2c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.51
TSHR P16473 2/20 0.51
ALDH1A1 P00352 4/20 0.47
KDM4E B2RXH2 2/20 0.47
P2RX3 P56373 1/20 0.46
P2RX7 Q99572 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
NPC1 O15118 2/20 0.45
HTT P42858 2/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
TP53 P04637 1/20 0.45
XBP1 P17861 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TLR9 Q9NR96 1/20 0.45
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
RAB9A P51151 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3530225 0.92 TSHR (0.51) MAPK1TSHRALDH1A1KDM4EP2RX3
SCHEMBL3293573 0.84 CSF1R (0.44) MAPK1TSHRALDH1A1KDM4ETDP1
SCHEMBL3526298 0.83 TSHR (0.54) MAPK1TSHRALDH1A1KDM4EP2RX3
SCHEMBL4574269 0.80 CSF1R (0.46) MAPK1TSHRALDH1A1KDM4ETDP1
SCHEMBL11873809 0.79 LMNA (0.52) MAPK1TSHRALDH1A1KDM4ETDP1
SCHEMBL16088468 0.76 PDE4A (0.46) MAPK1TSHRALDH1A1KDM4ENPC1
SCHEMBL3532297 0.76 ALDH1A1 (0.43) MAPK1ALDH1A1NPC1HTTMAPT
SCHEMBL11583159 0.75 LMNA (0.59) MAPK1TSHRALDH1A1KDM4ETDP1
SCHEMBL3293567 0.75 NPC1 (0.43) MAPK1ALDH1A1NPC1HTTMAPT
SCHEMBL4573769 0.75 CSF1R (0.43) MAPK1TSHRALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642270-B2 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2010-01-05 US disclosed
EP-1937681-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2008-07-02 EP disclosed
WO-2007033232-A1 5-OXO-5,8-DIHYDRO-PYRIDO-PYRIMIDINES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-03-22 WO disclosed
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060577-A1 5-Oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase FLT3, FES, FGR MAPK1 354/4885TSHR 1862/4885ALDH1A1 3590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.